Proliferating primary hepatocytes from the pUR288 lacZ plasmid mouse are valuable tools for genotoxicity assessment in vitro

Environmental and Molecular Mutagenesis

Volumn 53, Issue 5, 2012, Pages 376-383

  Zwart, Edwin P ^a   Schaap, Mirjam M ^a,b   van den Dungen, Myrthe W ^a   Braakhuis, Hedwig M ^a   White, Paul A ^c   Steeg, Harry van ^a,b   Benthem, Jan van ^a   Luijten, Mirjam ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HEALTH CANADA   (Canada)

Author keywords

Genotoxicity; In vitro; LacZ reporter gene; Primary mouse hepatocytes; Risk assessment

Indexed keywords

BENZO[A]PYRENE; BETA GALACTOSIDASE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A1; ETOPOSIDE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEASIBILITY STUDY; GENOTOXICITY; IN VITRO STUDY; LIVER CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; ULTRAVIOLET RADIATION; XENOBIOTIC METABOLISM;

MAMMALIA;

EID: 84862013561     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21700     Document Type: Article

References (48)

1. Anderson RD, Berger NA. 1994. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 309: 109-142.
2. Block GD, Locker J, Bowen WC, Petersen BE, Katyal S, Strom SC, Riley T, Howard TA, Michalopoulos GK. 1996. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol 132: 1133-1149.
3. Boerrigter ME, Dollé ME, Martus HJ, Gossen JA, Vijg J. 1995. Plasmid-based transgenic mouse model for studying in vivo mutations. Nature 377: 657-659.
4. Bruins W, Bruning O, Jonker MJ, Zwart E, van der Hoeven TV, Pennings JL, Rauwerda H, de Vries A, Breit TM. 2008. The absence of Ser389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. Mol Cell Biol 28: 1974-1987.
5. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van Den BJ, Van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24: 8884-8894.
6. Cervenkova K, Belejova M, Vesely J, Chmela Z, Rypka M, Ulrichova J, Modriansky M, Maurel P. 2001. Cell suspensions, cell cultures, and tissue slices-important metabolic in vitro systems. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 145: 57-60.
7. Chen G, Gingerich J, Soper L, Douglas GR, White PA. 2010. Induction of lacZ mutations in MutaMouse primary hepatocytes. Environ Mol Mutagen 51: 330-337.
8. Choudhury RC, Palo AK, Sahu P. 2004. Cytogenetic risk assessment of etoposide from mouse bone marrow. J Appl Toxicol 24: 115-122.
9. de Smet K, Loyer P, Gilot D, Vercruysse A, Rogiers V, Guguen-Guillouzo C. 2001. Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem Pharmacol 61: 1293-1303.
10. de Vries A, Dollé ME, Broekhof JL, Muller JJ, Kroese ED, van Kreijl CF, Capel PJ, Vijg J, van Steeg H. 1997. Induction of DNA adducts and mutations in spleen, liver and lung of XPA- deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis 18: 2327-2332.
11. Dollé ME, Martus HJ, Gossen JA, Boerrigter ME, Vijg J. 1996. Evaluation of a plasmid-based transgenic mouse model for detecting in vivo mutations. Mutagenesis 11: 111-118.
12. Donato MT, Gomez-Lechon MJ, Castell JV. 1993. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 213: 29-33.
13. Dunn JC, Tompkins RG, Yarmush ML. 1991. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 7: 237-245.
14. Eckl PM, Raffelsberger I. 1997. The primary rat hepatocyte micronucleus assay: general features. Mutat Res 392: 117-124.
15. Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, Rogiers V. 2006. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 7: 629-660.
16. Fassett JT, Tobolt D, Nelsen CJ, Albrecht JH, Hansen LK. 2003. The role of collagen structure in mitogen stimulation of ERK, cyclin D1 expression, and G1-S progression in rat hepatocytes. J Biol Chem 278: 31691-31700.
17. Fowler P, Smith K, Young J, Jeffrey L, Kirkland D, Pfuhler S, Carmichael P. 2012. Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays. I. Choice of cell type 1. Mutat Res 742: 11-25.
18. Garcia AM, Busuttil RA, Rodriguez A, Cabrera C, Lundell M, Dolle ME, Vijg J. 2007. Detection and analysis of somatic mutations at a lacZ reporter locus in higher organisms: application to Mus musculus and Drosophila melanogaster. Methods Mol Biol 371: 267-287.
19. Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, Hewitt N, Ringel M, Hilz BR, Bader A, Langsch A, Koose T, Burger HJ, Maas J, Oesch F. 2003. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35: 145-213.
20. Gorelick NJ. 1995. Overview of mutation assays in transgenic mice for routine testing. Environ Mol Mutagen 25: 218-230.
21. Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, Ringel M, Swales N, Fischer T, Biefang K, Gerl M, Bottger T, Oesch F. 2000. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32: 81-118.
22. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. 2007. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39: 159-234.
23. Kern A, Bader A, Pichlmayr R, Sewing KF. 1997. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 54: 761-772.
24. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584: 1-256.
25. Kirkland D, Kasper P, Muller L, Corvi R, Speit G. 2008. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. Mutat Res 653: 99-108.
26. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Muller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P. 2007. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat Res 628: 31-55.
27. Lambert IB, Singer TM, Boucher SE, Douglas GR. 2005. Detailed review of transgenic rodent mutation assays. Mutat Res 590: 1-280.
28. Lu X. 2005. p53: a heavily dictated dictator of life and death. Curr Opin Genet Dev 15: 27-33.
29. Lynch A, Harvey J, Aylott M, Nicholas E, Burman M, Siddiqui A, Walker S, Rees R. 2003. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18: 345-353.
30. Mahabir AG, Zwart E, Schaap M, van Benthem J, de Vries A, Hernandez LG, Hendriksen CF, van Steeg H. 2009. LacZ mouse embryonic fibroblasts detect both clastogens and mutagens. Mutat Res 666: 50-56.
31. Mathijs K, Kienhuis AS, Brauers KJ, Jennen DG, Lahoz A, Kleinjans JC, van Delft JH. 2009. Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab Dispos 37: 1305-1311.
32. Muller-Tegethoff K, Kersten B, Kasper P, Muller L. 1997. Application of the in vitro rat hepatocyte micronucleus assay in genetic toxicology testing. Mutat Res 392: 125-138.
33. OECD. 1997. Test No. 476: In vitro Mammalian Cell Gene Mutation Test, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing.
34. Pfuhler S, Albertini S, Fautz R, Herbold B, Madle S, Utesch D, Poth A. 2007. Genetic toxicity assessment: employing the best science for human safety evaluation part IV: Recommendation of a working group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a simple and straightforward approach to genotoxicity testing. Toxicol Sci 97: 237-240.
35. Pfuhler S, Fellows M, van Benthem J, Corvi R, Curren R, Dearfield K, Fowler P, Frotschl R, Elhajouji A, Le Hegarat L, Kasamatsu T, Kojima H, Ouedraogo G, Scott A, Speit G. 2011. In vitro genotoxicity test approaches with better predictivity: summary of an IWGT workshop 3. Mutat Res 723: 101-107.
36. Rana B, Mischoulon D, Xie Y, Bucher NL, Farmer SR. 1994. Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response transcription factors. Mol Cell Biol 14: 5858-5869.
37. Recio L, Hobbs C, Caspary W, Witt KL. 2010. Dose-response assessment of four genotoxic chemicals in a combined mouse and rat micronucleus (MN) and Comet assay protocol. J Toxicol Sci 35: 149-162.
38. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, LeCluyse E. 2002. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 16: 89-99.
39. Rogiers V, Vercruysse A. 1993. Rat hepatocyte cultures and co-cultures in biotransformation studies of xenobiotics. Toxicology 82: 193-208.
40. Smart DJ, Halicka HD, Schmuck G, Traganos F, Darzynkiewicz Z, Williams GM. 2008. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat Res 641: 43-47.
41. Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, Jacobson-Kram D, Kirkland D, MacGregor JT, Marzin D, Ohyama W, Schuler M, Suzuki H, Zeiger E. 2007. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Mutat Res 627: 41-58.
42. van Kesteren PC, Zwart PE, Pennings JL, Gottschalk WH, Kleinjans JC, van Delft JH, van Steeg H, Luijten M. 2011. Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene. Toxicol Sci 123: 123-132.
43. van Steeg H, Mullenders LH, Vijg J. 2000. Mutagenesis and carcinogenesis in nucleotide excision repair-deficient XPA knock out mice. Mutat Res 450: 167-180.
44. Vijg J, Dolle ME, Martus HJ, Boerrigter ME. 1997. Transgenic mouse models for studying mutations in vivo: applications in aging research. Mech Ageing Dev 99: 257-271.
45. Viollon-Abadie C, Bigot-Lasserre D, Nicod L, Carmichael N, Richert L. 2000. Effects of model inducers on thyroxine UDP-glucuronosyl-transferase activity in vitro in rat and mouse hepatocyte cultures. Toxicol In Vitro 14: 505-512.
46. Westerink WM, Schoonen WG. 2007. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21: 1592-1602.
47. Woo RA, Poon RY. 2004. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev 18: 1317-1330.
48. Zhang J, Tian Q, Yung CS, Chuen LS, Zhou S, Duan W, Zhu YZ. 2005. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37: 611-703.